Max Formulations Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 20-12-2024
- Paid Up Capital ₹ 2.60 M
as on 20-12-2024
- Company Age 22 Year, 21 Days
- Last Filing with ROC 31 Mar 2006
- Open Charges ₹ 2.00 Cr
as on 20-12-2024
- Satisfied Charges ₹ 8.75 M
as on 20-12-2024
About Max Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2006. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.60 M.
The company currently has active open charges totaling ₹2.00 Cr. The company has closed loans amounting to ₹8.75 M, as per Ministry of Corporate Affairs (MCA) records.
Vaibhav Patil, Dhananjay Kale, and Kiran Patil serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PTC138530
- Company No.
138530
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jan 2003
- Date of AGM
30 Sep 2006
- Date of Balance Sheet
31 Mar 2006
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Max Formulations?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vaibhav Patil  | Director | 03-Jan-2003 | Current |
| Dhananjay Kale | Director | 22-Aug-2006 | Current |
| Kiran Patil | Director | 02-Apr-2008 | Current |
Financial Performance of Max Formulations.
Enhance accessibility to Max Formulations's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Max Formulations?
Unlock access to Max Formulations's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Vintage Real Estate And Properties Private LimitedActive 4 years 1 month
Vaibhav Patil is a mutual person
Charges (Loans)
₹20.00 M
₹8.75 M
Charges Breakdown by Lending Institutions
- The Hongkong And Shanghai Banking Corporation : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2007 | The Hongkong And Shanghai Banking Corporation | ₹2.00 Cr | Open |
| 22 May 2003 | Bank Of India | ₹8.75 M | Satisfied |
How Many Employees Work at Max Formulations?
Unlock and access historical data on people associated with Max Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Max Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Max Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.